Research – Norovirus tablet vaccine shows positive results in Phase 1 study

Outbreak Today

Vaxart, Inc., a clinical-stage biotechnology company developing oral recombinant vaccines that are administered by tablet rather than by injection, announced Tuesday that its norovirus tablet vaccine met the primary and secondary endpoints for safety and immunogenicity in a Phase 1 clinical trial.